Hyundai Bioscience: "Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread"

May 20, 2026

Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.

Hyundai Bioscience stated that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for XAFTY®, it can immediately provide products currently in stock.

According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus.

The company reported, "In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far," and claimed that "in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative."

Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.

CONTACT: Jason Kim [email protected] (562) 964-3910

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.